CME Group (CME) director Martin Gepsman sells 300 shares in open market

Rhea-AI Filing Summary

CME Group Inc. director Martin J. Gepsman reported an open-market sale of Class A common stock. He sold 300 shares at a price of $305.90 per share. After this sale, he directly owns 24,999 shares of CME Group Class A common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GEPSMAN MARTIN J

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	02/20/2026		S		300	D	$305.9	24,999	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	By: Margaret Austin Wright For: Martin J. Gepsman	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CME (CME) director Martin J. Gepsman report?

Martin J. Gepsman reported selling 300 shares of CME Group Class A common stock in an open-market transaction. The sale was disclosed on a Form 4 insider filing, documenting changes in his direct ownership position in the company.

At what price were the CME (CME) shares sold by director Martin J. Gepsman?

The 300 CME Group Class A common shares were sold at $305.90 per share. This price reflects the execution level for this particular open-market transaction, as reported in the Form 4 insider trading disclosure for the director.

How many CME (CME) shares does Martin J. Gepsman own after the reported sale?

After selling 300 shares, Martin J. Gepsman directly owns 24,999 CME Group Class A common shares. This remaining balance is disclosed in the Form 4 as his direct ownership position following the reported open-market sale transaction.

What type of transaction did CME (CME) director Martin J. Gepsman execute?

The transaction was an open-market sale of common stock, coded as “S” on Form 4. This code indicates a sale in the open market or a private transaction, rather than a stock option exercise, grant, or other non-market-related equity event.

Does the CME (CME) Form 4 indicate if Martin J. Gepsman’s ownership is direct or indirect?

The Form 4 shows that Martin J. Gepsman’s remaining 24,999 CME Group shares are held with direct ownership. The filing classifies his ownership type as “D,” meaning the shares are not reported as being held through an intermediary entity.